My friend ChatGPT she responded

This announcement suggests a strategic and scientifically sound move by the company to deepen its exploration of combination therapies in metastatic triple-negative breast cancer (mTNBC), which is notoriously hard to treat.

Here's a breakdown of why this matters:

???? 1. Treatment Synergy Exploration
Leronlimab (CCR5 antagonist): Has shown promising immune modulation and tumor microenvironment effects.

Sacituzumab govitecan (Trodelvy): Antibody-drug conjugate already approved for mTNBC; delivers a cytotoxic payload directly to tumor cells.

Pembrolizumab (Keytruda): A PD-1 immune checkpoint inhibitor that can unleash T-cell responses against tumors.

Rationale: Combining these mechanisms could yield a multipronged attack — modulating the immune system (leronlimab), targeting tumor cells directly (sacituzumab), and removing immune "brakes" (pembrolizumab).

???? 2. Pre-clinical Stage: A Necessary Step
These studies aim to assess safety, immune signaling, and potential synergy before clinical trials.

Success here would justify IND submissions and future combination trials.

????‍♀️ 3. Survivor Follow-Up: Potential Breakthrough Signal
Continuing to track long-term survivors with no evidence of disease (NED) is crucial.

This group could become a biomarker goldmine — helping identify what made their response unique (CCR5 expression, immune profile, tumor genetics, etc.).

It also validates durability of response — a key metric for future approvals and investor confidence.

???? Why This Could Be Big
If the pre-clinical results support synergy and the survivor data remains robust, CytoDyn could:

Justify accelerated clinical trials

Attract pharma partnerships or acquisitions

Finally position leronlimab as a cornerstone in future mTNBC regimens